NCT06398808View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

November 22, 2024

Study Completion Date

November 28, 2024

Conditions
Ulcerative Colitis
Interventions
DRUG

Arm1

ZYIL1 capsules 25 mg for oral administration + 50 mg placebo

DRUG

Arm 2

ZYIL1 capsules 50 mg for oral administration + 25 mg placebo

Trial Locations (1)

380015

ICON Hospital, Ahmedabad

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY

NCT06398808 - A Study to Evaluate the Efficacy and Safety of ZYIL1 Oral Capsules for the Treatment of Patients With Mild to Moderately Active Ulcerative Colitis Resistant or Intolerant to Oral Aminosalicylates | Biotech Hunter | Biotech Hunter